Abstract
The antiplatelet effects of a novel guanidine derivative, KR-32570 ([5-(2-methoxy-5-chlorophenyl) furan-2-ylcarbonyl]guanidine), were investigated with an emphasis on the mechanisms underlying its inhibition of collagen-induced platelet aggregation. KR-32570 significantly inhibited the aggregation of washed rabbit platelets induced by collagen (10 μg/mL), thrombin (0.05 U/mL), arachidonic acid (100 μM), a thromboxane (TX) A2 mimetic agent U46619 (9,11-dideoxy-9,11-methanoepoxy-prostaglandin F2, 1 μM) and a Ca2+ ATPase inhibitor thapsigargin (0.5 μM) (IC50 values: 13.8±1.8, 26.3±1.2, 8.5±0.9, 4.3±1.7 and 49.8±1.4 μM, respectively). KR-32570 inhibited the collagen-induced liberation of [3H]arachidonic acid from the platelets in a concentration dependent manner with complete inhibition being observed at 50 μM. The TXA2 synthase assay showed that KR-32570 also inhibited the conversion of the substrate PGH2 to TXB2 at all concentrations. Furthermore, KR-32570 significantly inhibited the [Ca2+]i mobilization induced by collagen at 50 μM, which is the concentration that completely inhibits platelet aggregation. KR-32570 also decreased the level of collagen (10 μg/mL)-induced secretion of serotonin from the dense-granule contents of platelets, and inhibited the NHE-1-mediated rabbit platelet swelling induced by intracellular acidification. These results suggest that the antiplatelet activity of KR-32570 against collagen-induced platelet aggregation is mediated mainly by inhibiting the release of arachidonic acid, TXA2 synthase, the mobilization of cytosolic Ca2+ and NHE-1.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Balsinde, J., Winstead, M. V., and Dennis, E. A., Phospholipase A(2) regulation of arachidonic acid mobilization.FEBS Lett., 531, 2–6 (2002).
Born, G. V. and Cross, M. J., The aggregation of blood platelets.J. Physiol., 168, 178–195 (1963).
Corti, R., Farkouh, M. E., and Badimon, J. J., The vulnerable plaque, acute coronary syndromes.Am. J. Med., 113, 668–680 (2002).
Corti, R., Fuster, V., and Badimon, J. J., Pathogenetic concepts of acute coronary syndromes.J. Am. Coll. Cardiol., 41, 7S-14S (2003).
Drayer, A. L., Meima, M. E., Derks, M. W., Tuik, R., and van Haastert, P. J., Mutation of an EF-hand Ca(2+)-binding motif in phospholipase C of Dictyostelium discoideum: inhibition of activity but no effect on Ca2+-dependence.Biochem. J., 311, 505–510 (1995).
Holmsen, H. and Dangelmarier, C. A., Measurement of secretion of serotonin.Methods Enzymol., 169, 205–210 (1989).
Jackson, S. P., Nesbitt, W. S., and Kulkarni, S., Signaling events underlying thrombus formation.J. Thromb. Haemost., 1, 1602–1612 (2003).
Jin, Y. R., Cho, M. R., Ryu, C. K., Chung, J. H., Yuk, D. Y., Hong, J. T., andet al., Antiplatelet activity of J78, an antithrombotic agent, is mediated by TXA2 receptor blockade with TXA2 synthase inhibition, suppression of cytosolic Ca2+ mobilization.J. Pharmacol. Exp. Ther., 312, 214–219 (2005).
Jneid, H., Bhatt, D. L., Corti, R., Badimon, J. J., Fuster, V., and Francis, G. S., Aspirin, clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study.Arch. Intern. Med., 163, 1145–1153 (2003).
Karmazyn, M., Gan, X. T., Humphreys, R. A., Yoshida, H., and Kusumoto, K., The myocardial Na+−H+ exchange: structure, regulation, its role in heart disease.Circ. Res., 85, 777–786 (1999).
Karmazyn, M., Role of sodium-hydrogen exchange in cardiac hypertrophy, heart failure: a novel, promising therapeutic target.Basic. Res. Cardiol., 96, 325–328 (2001).
Klages, B., Brandt, U., Simon, M. I., Schultz, G., and Offermanns, S., Activation of G12/G13 results in shape change, Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets.J. Cell. Biol., 144, 745–754 (1999).
Knight, D. R., Smith, A. H., Flynn, D. M., MacAndrew, J. T., Ellery, S. S., Kong, J. X., Marala, R. B., Wester, R. T., Guzman-Perez, A., Hill, R. J., Magee, W. P., and Tracey, W. R., A novel sodium-hydrogen exchanger isoform-1 inhibitor, zoniporide, reduces ischemic myocardial injuryin vitro andin vivo.J. Pharmacol. Exp. Ther., 297 (1), 254–259 (2001).
Kusumoto, K., Igata, H., Abe, A., Ikeda, S., Tsuboi, A., Imamiya, E., Fukumoto, S., Shiraishi, M., and Watanabe, T.,In vitro andin vivo pharmacology of a structurally novel Na+−H+ exchange inhibitor, T-162559.Br. J. Pharmacol., 135(8), 1995–2003 (2002).
Lapetina, E. G., The signal transduction induced by thrombin in human platelets.FEBS Lett., 268, 400–404 (1990).
Marala, R. B., Brown, J. A., Kong, J. X., Tracey, W. R., Knight, D. R., Wester, R. T., Sun, D., Kennedy, S. P., Hamanaka, E. S., Ruggeri, R. B., and Hill, R. J., Zoniporide: a potent and highly selective inhibitor of human Na+/H+ exchanger-1.Eur. J. Pharmacol., 451(1), 37–41 (2002).
Mentzer, R. M. Jr, Lasley, R. D., Jessel, A., and Karmazy M., Intracellular sodium hydrogen exchange inhibition, clinical myocardial protection.Ann. Thorac. Surg., 75, S700-S708 (2003).
Offermanns, S., Laugwitz, K. L., Spicher, K., and Schultz, G., G proteins of the G12 family are activatedvia thromboxane A2, thrombin receptors in human platelets.Proc. Natl. Acad. Sci., 91, 504–508 (1994).
Raychowdhury, M. K., Yukawa, M., Collins, L. J., McGrail, S. H., Kent, K. C., and Ware, J. A., Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor.J. Biol. Chem., 269, 19256–19261 (1994).
Roberts, D. E., McNicol, A., and Bose R., Mechanism of collagen activation in human platelets.J. Biol. Chem., 279, 19421–19430 (2004).
Rosskopf, D., Sodium-hydrogen exchange, platelet function.J. Thromb. Thrombolysis., 8, 15–24 (1999).
Rosskopf, D., Morgenstern, E., Scholz, W., Osswald, U., and Siffert, W., Rapid determination of the elevated Na+−H+ exchange in platelets of patients with essential hypertension using an optical swelling assay.J. Hypertens., 9(3), 231–238 (1991).
Ruiz-Meana, M., Garcia-Dorado, D., Pina, P., Inserte, J., Agullo, L., and Soler-Soler, J., Cariporide preserves mitochondrial proton gradient, delays ATP depletion in cardiomyocytes during ischemic conditions.Am. J. Physiol. Heart. Circ. Physiol., 285, H999–1006 (2003).
Schlienger, R. G. and Meier, C. R., Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction?Am. J. Cardiovasc. Drugs., 3, 149–162 (2003).
Siffert, W., Regulation of platelet function by sodium-hydrogen exchange.Cardiovasc. Res., 29, 160–166 (1995).
Stelmach, H., Rusak, T., and Tomasiak, M., The involvement of the Na+/H+ exchanger in the formation of microvesicles by porcine platelets.Haematologia (Budap), 32, 239–252 (2002).
The RAPT Investigators, Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor, thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT).Circulation, 89, 588–595 (1994).
Touret, N., Tanneur, V., Godart, H., Seidler, R., Taki, N., and Burger, E.,et al., Characterization of sabiporide, a new specific NHE-1 inhibitor exhibiting slow dissociation kinetics, cardioprotective effects.Eur. J. Pharmacol., 459, 151–158 (2003).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, KS., Park, JW., Jin, YR. et al. Antiplatelet activity of [5-(2-methoxy-5-chlorophenyl)furan-2-ylcarbonyl]guanidine (KR-32570), a novel sodium/hydrogen exchanger-1 and its mechanism of action. Arch Pharm Res 29, 375–383 (2006). https://doi.org/10.1007/BF02968587
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02968587